Lyka Labs Ltd Stock Falls to 52-Week Low of Rs.61.03 Amidst Continued Downtrend

Stock Performance and Market Context

On 24 Feb 2026, Lyka Labs Ltd’s share price touched Rs.61.03, the lowest level in the past year. This decline comes after a continuous 10-day losing streak, during which the stock has fallen by 14.43%. The day’s performance saw the stock underperform its Pharmaceuticals & Biotechnology sector by 0.91%, further emphasising the downward momentum.

Lyka Labs is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish sentiment. This contrasts with the broader market, where the Sensex, despite a negative opening and a fall of 524.23 points (-0.92%) to 82,528.31, remains 4.4% below its 52-week high of 86,159.02. The Sensex’s 50-day moving average remains above its 200-day moving average, indicating a more stable medium-term trend compared to Lyka Labs.

Over the last year, Lyka Labs has delivered a total return of -45.23%, significantly lagging the Sensex’s positive 10.83% return. The stock’s 52-week high was Rs.128.60, highlighting the steep decline experienced over the period.

Financial Metrics and Fundamental Assessment

Lyka Labs Ltd’s financial profile continues to reflect challenges. The company is classified as a high debt entity, with an average debt-to-equity ratio of 2.98 times, indicating significant leverage. This elevated debt level has contributed to a weak long-term fundamental strength assessment.

Operating profit growth has been negative over the last five years, with an annualised decline rate of 170.47%. The latest quarterly results for December 2025 further underline this trend, with profit before tax (excluding other income) falling by 148.18% to a loss of Rs.1.32 crore. Net sales for the quarter were at a low Rs.30.73 crore, while the profit after tax stood at zero, marking a 100% decline compared to previous periods.

The company’s profitability has deteriorated sharply, with profits falling by 116% over the past year. This has contributed to the stock’s classification as a “Strong Sell” with a Mojo Score of 3.0, downgraded from a previous “Sell” rating on 12 Jan 2026. The market capitalisation grade stands at 4, reflecting the company’s relative size and valuation concerns.

Relative Performance and Risk Considerations

Lyka Labs has consistently underperformed the BSE500 benchmark over the last three annual periods, compounding investor concerns. The stock’s risk profile is elevated, trading at valuations that are considered risky relative to its historical averages. This is underscored by the stock’s negative returns and declining profitability, which have not aligned with broader sector or market trends.

The majority shareholding remains with the promoters, which may influence strategic decisions and capital allocation going forward.

Summary of Key Concerns

The stock’s fall to Rs.61.03 represents a culmination of several factors: sustained negative returns, weak sales and profit figures, high leverage, and a downgrade in fundamental grading. Despite the broader market’s relative resilience, Lyka Labs has struggled to maintain momentum, reflected in its trading below all major moving averages and consistent underperformance against sector and benchmark indices.

While the Sensex remains within 5% of its 52-week high, Lyka Labs’ stock price is less than half of its peak level in the same period, underscoring the divergence in performance. The company’s financial metrics, including a negative operating profit trend and elevated debt, continue to weigh on market sentiment.

Investors and analysts will continue to monitor the company’s quarterly results and financial health metrics to assess any shifts in trajectory. For now, the stock remains positioned at a significant low point within its annual trading range.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today